Navigation Links
Combination therapy provides hope for cure of dangerous infections of cystic fibrosis patients
Date:4/24/2011

Hamilton, ON (April 24, 2011) An over-the-counter drug used to treat diarrhea combined with minocycline, an antibiotic used to treat bacterial infections, could one day change the lives of those living with cystic fibrosis.

Researchers at McMaster University have discovered this creative approach to tackle antibiotic resistance to bacterial infections, a frequent complication of those with cystic fibrosis. Cystic fibrosis is the most common, fatal genetic disease affecting Canadian children and young adults.

"Antibiotic resistance is having a profound effect on known drugs that are used to treat illness and disease," says researcher Eric Brown, professor and chair of McMaster's Department of Biochemistry and Biomedical Sciences and member of the Michael G. DeGroote Institute for Infectious Disease Research (IIDR).

"Previous advances in treating cystic fibrosis have been in managing infection, but since infectious organisms are increasingly developing resistance to antibiotics, the importance of providing new treatments is more important than ever."

Brown, who made the discovery in collaboration with McMaster researchers Gerry Wright and Brian Coombes, found that the combination of these two drugs inhibits the growth of bacteria after screening a collection of previously approved non-antibiotic drugs within McMaster's Centre for Microbial Chemical Biology.

Their screening revealed that this particular combination using the anti-diarrhea drug loperamide increases the efficacy of the antibiotic minocycline against multidrug resistant P. aeruginosa.

"Typically it takes 13 to 15 years to develop a drug," says Brown. "We think that this approach could cut drug development time in half."

"These exciting research findings hold promise that a new, safer method for treating devastating lung infections in people with cystic fibrosis may be just around the corner," says Maureen Adamson, CEO, Cystic Fibrosis Ca
'/>"/>

Contact: Laura Thompson
lthomp@mcmaster.ca
905-525-9140, ext. 22196
McMaster University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Killing drug-resistant melanoma requires combination therapy
2. Combination therapy reduced HER2-positive breast cancers
3. Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer
4. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
5. Grape news: New treatment combination safe alternative to sulfur dioxide
6. Study: Grass, fungus combination affects ecology
7. Investigators identify cleat/natural grass combination may be less likely to result in ACL injury
8. Diabetes drug kills cancer stem cells in combination treatment in mice
9. Old stain in a new combination
10. Novel therapy improves immune function in teen with rare disease
11. Umbilical cord blood-derived stem cells studied for lupus therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... several disciplines will be celebrated tonight at the third ... improving the health of premature infants and in paving ... researchers, whose work was supported by the National Science ... Atomic Energy Commission, will be honored at a ceremony ... bipartisan group of Members of Congress will be on ...
(Date:9/18/2014)... world-leading provider of scientific, technical and medical information ... Society (ARMS), recognized the academic research achievements of ... Researcher of the Year Awards. , The award ... Centre and in conjunction with the ARMS 2014 ... and New Zealand,s scientific community. Guest of honour ...
(Date:9/18/2014)... form of camouflage: you don,t just blend in, the ... as uncommon as you might think. Kathryn Feller, from ... the larval life stages of many marine species are ... that most creatures cannot make transparent. Feller explains that ... individual eye unit with an opaque pigment to prevent ...
Breaking Biology News(10 mins):3rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Transparent larvae hide opaque eyes behind reflections 2
... It may be news to its bankers, but Charlotte, the biggest ... financial industry, is actually an old growth forest. At least ... Charlotte is famous for having two kinds of green. It is ... residential neighborhoods and near-suburbs are also known for their lush yards ...
... Health Research Charity --Presents 2007 Prizes ,for Outstanding Psychiatric ... Prize winners have significantly contributed to the ... mental disorders NEW YORK, N.Y., Oct. 16, 2007Five ... be presented to scientists of great achievement by NARSAD, ...
... German . , Mammography continues to be ... breast cancer. However, because this technique is not as ... not deliver reliable results for every level of tissue ... works with rays of near-infrared (NIR) light instead of ...
Cached Biology News:Ecologists discover city is 'uber-forest' for big owls 2Ecologists discover city is 'uber-forest' for big owls 3Ecologists discover city is 'uber-forest' for big owls 4Ecologists discover city is 'uber-forest' for big owls 5Ecologists discover city is 'uber-forest' for big owls 6NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research 2NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research 3NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research 4NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research 5Contrast agent trials in swine 2
(Date:9/17/2014)... Terracon Corporation has announced the introduction ... . This addition to the company’s industry-leading line ... polyethylene and available in 125 or 250 gallon capacities. ... two weeks or less. , The new pre-engineered TerraPure ... Terracon’s existing TerraPure tank line – plus quick turnaround. ...
(Date:9/17/2014)... , Sept. 17, 2014 Hussey ... of MD-Cu 29 antimicrobial copper, announces Gilmour Academy ... to the first EPA-registered antimicrobial solid touch surface to ... is a reasonably priced surface that kills greater than ... hours of exposure. 1 , ...
(Date:9/17/2014)... 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: ... proprietary technologies and products for advanced microarray diagnostics, today ... trading in the United States ... commence on September 17, 2014 on the OTCQX under ... on the TSX Venture Exchange under its existing symbol ...
(Date:9/17/2014)... MARLBOROUGH, Mass. , Sept. 17, 2014 /PRNewswire/ ... ), a biotechnology company focused on discovering, developing ... needs using RNA-targeted technologies, today announced that it has ... Patent and Trademark Office on its unique delivery ... ® ) to phagocytic cells for the treatment ...
Breaking Biology Technology:Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4
... proxy, FOR the Election of, Two ... May 15 /PRNewswire/ - The Concerned Shareholders of Biovail ... (TSX:BVF) continues to mislead its shareholders by making the ... requisition was simply about governance reform and has already ...
... Nile Therapeutics, Inc. (Nasdaq: NLTX ... therapeutics for heart failure patients, received notification from the ... has released the Company,s CD-NP development program from clinical ... the FDA the finalized protocol for the Company,s planned ...
... Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced ... 15 Proteolix, Inc. today announced that data from ... solid tumors will be presented at the 2009 Annual ... being held May 29 - June 2, 2009 in ...
Cached Biology Technology:The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 2The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 3The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 4The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 5The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 6The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 7Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA 2Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA 3Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting 2Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting 3
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
... OA-Hy cis- 9-Octadecenoyl-N-hydroxylamide Oleoyl-N-hydroxylamide ... INERT GAS. A potent inhibitor of MMP-2 ... i = 1.7 μM). Purity: ... or DMSO. Unstable in solution, reconstitute just ...
MAb to Vasopressin Preservative: NaN3...
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
Biology Products: